Symbols / SNSE
SNSE Chart
About
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its solnerstotug program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 39.62M |
| Enterprise Value | 20.15M | Income | -24.14M | Sales | — |
| Book/sh | 18.24 | Cash/sh | 19.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 14 | IPO | — |
| P/E | — | Forward P/E | -28.04 | PEG | — |
| P/S | — | P/B | 1.72 | P/C | — |
| EV/EBITDA | -0.86 | EV/Sales | — | Quick Ratio | 5.64 |
| Current Ratio | 5.81 | Debt/Eq | 8.78 | LT Debt/Eq | — |
| EPS (ttm) | -19.14 | EPS next Y | -1.12 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 07:00 | ROA | -37.04% |
| ROE | -70.18% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.26M |
| Shs Float | 858.19K | Short Float | 3.08% | Short Ratio | 0.25 |
| Short Interest | — | 52W High | 34.52 | 52W Low | 5.00 |
| Beta | 0.28 | Avg Volume | 310.36K | Volume | 88.98K |
| Target Price | — | Recom | None | Prev Close | $34.23 |
| Price | $31.40 | Change | -8.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$31.40
Latest analyst target
3. DCF / Fair value
$-189.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.40
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-30 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-08-05 | main | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-28 | main | Oppenheimer | Outperform → Outperform | $4 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-08-07 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-05-24 | reit | Stephens & Co. | Overweight → Overweight | $5 |
| 2024-05-14 | init | Stephens & Co. | — → Overweight | $5 |
| 2023-12-04 | init | HC Wainwright & Co. | — → Buy | $4 |
| 2022-12-13 | init | Citigroup | — → Buy | $6 |
| 2022-10-03 | up | Oppenheimer | Perform → Outperform | $5 |
| 2022-03-10 | main | Piper Sandler | — → Overweight | $10 |
| 2021-07-01 | down | Berenberg | Buy → Hold | $12 |
| 2021-06-29 | down | Oppenheimer | Outperform → Perform | — |
| 2021-03-01 | init | Oppenheimer | — → Outperform | $36 |
| 2021-03-01 | init | Piper Sandler | — → Overweight | $25 |
- $SNSE stock is down 15% today. Here's what we see in our data. - Quiver Quantitative hu, 26 Feb 2026 14
- Sensei Biotherapeutics hands new COO 1.24M stock options - Stock Titan Wed, 25 Feb 2026 11
- SNSE stock surges to 21-month high – everything to know about its Faeth Therapeutics acquisition - MSN Wed, 25 Feb 2026 05
- SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition - Stocktwits Wed, 18 Feb 2026 17
- SNSE: Stock-for-stock acquisition and $200M financing accelerate clinical development of novel cancer therapies - TradingView Wed, 18 Feb 2026 13
- Trading Systems Reacting to (SNSE) Volatility - Stock Traders Daily Sat, 21 Feb 2026 17
- Sensei Biotherapeutics grants stock options to 17 new employees By Investing.com - Investing.com Nigeria Wed, 25 Feb 2026 14
- Market Movers | Winners: NDLS, RXT, SNSE | Losers: SSKN, NAK, OLB - Trefis hu, 19 Feb 2026 04
- What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump? - Benzinga Fri, 05 Dec 2025 08
- Sensei Biotherapeutics (SNSE) Shares Soar After $200M Acquisitio - GuruFocus Wed, 18 Feb 2026 17
- Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement - Yahoo Finance Wed, 18 Feb 2026 13
- Sensei Biotherapeutics (Nasdaq: SNSE) initiates strategic review, reduces workforce 65% - Stock Titan Fri, 14 Nov 2025 08
- How SNSE Inc (SNSE) Affects Rotational Strategy Timing - Stock Traders Daily ue, 10 Feb 2026 08
- Sensei Biotherapeutics (SNSE) COO and director added as SEC insider - Stock Titan Fri, 20 Feb 2026 02
- $SNSE stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 23 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6612 | 54575 | — | Sale at price 7.92 - 8.59 per share. | PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | I |
| 1 | 6612 | 54575 | — | Sale at price 7.92 - 8.59 per share. | CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | D |
| 2 | 395 | 2528 | — | Conversion of Exercise of derivative security at price 6.40 per share. | PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | I |
| 3 | 395 | 2528 | — | Conversion of Exercise of derivative security at price 6.40 per share. | CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-09 00:00:00 | D |
| 4 | 21295 | 228061 | — | Sale at price 9.06 - 11.40 per share. | PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-05 00:00:00 | I |
| 5 | 21295 | 228061 | — | Sale at price 9.06 - 11.40 per share. | CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-05 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -27.79M | -32.30M | -47.02M | -36.01M |
| TotalUnusualItems | -951.00K | -302.00K | 0.00 | 567.00K |
| TotalUnusualItemsExcludingGoodwill | -951.00K | -302.00K | 0.00 | 567.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -30.16M | -34.10M | -48.59M | -36.79M |
| ReconciledDepreciation | 1.32M | 1.35M | 1.35M | 685.00K |
| EBITDA | -28.75M | -32.61M | -47.02M | -35.44M |
| EBIT | -30.07M | -33.96M | -48.37M | -36.12M |
| NetInterestIncome | 2.46M | 3.48M | 1.56M | 130.00K |
| InterestExpense | 90.00K | 144.00K | 219.00K | 670.00K |
| InterestIncome | 2.55M | 3.62M | 1.78M | 800.00K |
| NormalizedIncome | -29.21M | -33.80M | -48.59M | -37.36M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -30.16M | -34.10M | -48.59M | -36.79M |
| TotalExpenses | 31.66M | 37.06M | 50.19M | 37.48M |
| TotalOperatingIncomeAsReported | -32.61M | -37.06M | -50.19M | -37.48M |
| DilutedAverageShares | 1.26M | 1.40M | 1.54M | 1.39M |
| BasicAverageShares | 1.26M | 1.40M | 1.54M | 1.39M |
| DilutedEPS | -24.00 | -24.40 | -31.60 | -26.60 |
| BasicEPS | -24.00 | -24.40 | -31.60 | -26.60 |
| DilutedNIAvailtoComStockholders | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncomeCommonStockholders | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncome | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncomeIncludingNoncontrollingInterests | -30.16M | -34.10M | -48.59M | -36.79M |
| NetIncomeContinuousOperations | -30.16M | -34.10M | -48.59M | -36.79M |
| PretaxIncome | -30.16M | -34.10M | -48.59M | -36.79M |
| OtherIncomeExpense | -954.00K | -517.00K | 36.00K | 558.00K |
| OtherNonOperatingIncomeExpenses | -3.00K | -215.00K | 36.00K | -9.00K |
| SpecialIncomeCharges | -951.00K | -302.00K | 0.00 | 567.00K |
| GainOnSaleOfPPE | 0.00 | -302.00K | 0.00 | -9.00K |
| OtherSpecialCharges | -567.00K | |||
| ImpairmentOfCapitalAssets | 951.00K | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | 2.46M | 3.48M | 1.56M | 130.00K |
| InterestExpenseNonOperating | 90.00K | 144.00K | 219.00K | 670.00K |
| InterestIncomeNonOperating | 2.55M | 3.62M | 1.78M | 800.00K |
| OperatingIncome | -31.66M | -37.06M | -50.19M | -37.48M |
| OperatingExpense | 31.66M | 37.06M | 50.19M | 37.48M |
| ResearchAndDevelopment | 18.63M | 18.30M | 30.38M | 21.66M |
| SellingGeneralAndAdministration | 13.04M | 18.77M | 19.80M | 15.82M |
| GeneralAndAdministrativeExpense | 13.04M | 18.77M | 19.80M | 15.82M |
| OtherGandA | 13.04M | 18.77M | 19.80M | 15.82M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.26M | 1.25M | 1.54M | 1.53M |
| ShareIssued | 1.26M | 1.25M | 1.54M | 1.53M |
| TotalDebt | 3.85M | 6.21M | 8.03M | 2.35M |
| TangibleBookValue | 38.39M | 64.89M | 103.41M | 146.51M |
| InvestedCapital | 38.39M | 64.89M | 103.41M | 146.51M |
| WorkingCapital | 36.48M | 61.61M | 99.52M | 143.65M |
| NetTangibleAssets | 38.39M | 64.89M | 103.41M | 146.51M |
| CapitalLeaseObligations | 3.85M | 6.21M | 8.03M | 2.35M |
| CommonStockEquity | 38.39M | 64.89M | 103.41M | 146.51M |
| TotalCapitalization | 38.39M | 64.89M | 103.41M | 146.51M |
| TotalEquityGrossMinorityInterest | 38.39M | 64.89M | 103.41M | 146.51M |
| StockholdersEquity | 38.39M | 64.89M | 103.41M | 146.51M |
| GainsLossesNotAffectingRetainedEarnings | -13.00K | -209.00K | -1.00M | -333.00K |
| OtherEquityAdjustments | -13.00K | -209.00K | -1.00M | -333.00K |
| RetainedEarnings | -262.05M | -231.90M | -197.79M | -149.21M |
| AdditionalPaidInCapital | 300.45M | 297.00M | 302.20M | 296.05M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 3.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 6.97M | 9.48M | 14.97M | 6.71M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.53M | 3.84M | 5.90M | 1.82M |
| OtherNonCurrentLiabilities | 67.00K | 149.00K | ||
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 1.53M | 3.77M | 5.90M | 1.67M |
| LongTermCapitalLeaseObligation | 1.53M | 3.77M | 5.90M | 1.67M |
| CurrentLiabilities | 5.45M | 5.64M | 9.07M | 4.89M |
| CurrentDebtAndCapitalLeaseObligation | 2.32M | 2.44M | 2.13M | 680.00K |
| CurrentCapitalLeaseObligation | 2.32M | 2.44M | 2.13M | 680.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.88M | 1.51M | 2.46M | 1.75M |
| PayablesAndAccruedExpenses | 1.25M | 1.69M | 4.47M | 2.46M |
| Payables | 2.46M | |||
| AccountsPayable | 2.46M | |||
| TotalAssets | 45.36M | 74.37M | 118.38M | 153.22M |
| TotalNonCurrentAssets | 3.43M | 7.12M | 9.79M | 4.68M |
| OtherNonCurrentAssets | 48.00K | 86.00K | 63.00K | 39.00K |
| NetPPE | 3.38M | 7.04M | 9.72M | 4.64M |
| AccumulatedDepreciation | -1.50M | -1.73M | -1.44M | -1.19M |
| GrossPPE | 4.88M | 8.77M | 11.17M | 5.83M |
| Leases | 253.00K | 253.00K | 253.00K | 253.00K |
| OtherProperties | 4.27M | 7.98M | 10.38M | 4.97M |
| MachineryFurnitureEquipment | 354.00K | 532.00K | 532.00K | 606.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 41.93M | 67.25M | 108.59M | 148.54M |
| OtherCurrentAssets | 120.00K | 325.00K | 344.00K | 374.00K |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 474.00K | 1.17M | 1.13M | 547.00K |
| CashCashEquivalentsAndShortTermInvestments | 41.34M | 65.76M | 107.12M | 147.62M |
| OtherShortTermInvestments | 31.34M | 52.75M | 89.32M | 140.46M |
| CashAndCashEquivalents | 9.99M | 13.01M | 17.80M | 7.16M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -24.82M | -32.20M | -39.35M | -32.28M |
| RepurchaseOfCapitalStock | 0.00 | -10.38M | 0.00 | |
| RepaymentOfDebt | -811.00K | -761.00K | -629.00K | -255.00K |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 0.00 | 164.09M | ||
| CapitalExpenditure | -146.00K | -180.00K | -321.00K | -2.03M |
| InterestPaidSupplementalData | 0.00 | 57.00K | ||
| EndCashPosition | 9.99M | 13.01M | 17.80M | 7.16M |
| BeginningCashPosition | 13.01M | 17.80M | 7.16M | 16.60M |
| ChangesInCash | -3.02M | -4.78M | 10.64M | -9.44M |
| FinancingCashFlow | -787.00K | -11.17M | -287.00K | 163.94M |
| CashFlowFromContinuingFinancingActivities | -787.00K | -11.17M | -287.00K | 163.94M |
| NetOtherFinancingCharges | -10.00K | -76.00K | ||
| ProceedsFromStockOptionExercised | 34.00K | 48.00K | 342.00K | 109.00K |
| NetPreferredStockIssuance | 0.00 | 23.49M | ||
| PreferredStockIssuance | 0.00 | 23.49M | ||
| NetCommonStockIssuance | 0.00 | -10.38M | 0.00 | 140.59M |
| CommonStockPayments | 0.00 | -10.38M | 0.00 | |
| CommonStockIssuance | 0.00 | 140.59M | ||
| NetIssuancePaymentsOfDebt | -811.00K | -761.00K | -629.00K | -255.00K |
| NetLongTermDebtIssuance | -811.00K | -761.00K | -629.00K | -255.00K |
| LongTermDebtPayments | -811.00K | -761.00K | -629.00K | -255.00K |
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 22.44M | 38.41M | 49.95M | -143.12M |
| CashFlowFromContinuingInvestingActivities | 22.44M | 38.41M | 49.95M | -143.12M |
| NetInvestmentPurchaseAndSale | 22.59M | 38.43M | 50.26M | -141.41M |
| SaleOfInvestment | 67.18M | 59.58M | 97.12M | 42.26M |
| PurchaseOfInvestment | -44.59M | -21.15M | -46.87M | -183.67M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -146.00K | -14.00K | -306.00K | -1.71M |
| SaleOfPPE | 0.00 | 166.00K | 15.00K | 318.00K |
| PurchaseOfPPE | -146.00K | -180.00K | -321.00K | -2.03M |
| OperatingCashFlow | -24.67M | -32.02M | -39.03M | -30.26M |
| CashFlowFromContinuingOperatingActivities | -24.67M | -32.02M | -39.03M | -30.26M |
| ChangeInWorkingCapital | -489.00K | -4.33M | 1.01M | 117.00K |
| ChangeInOtherWorkingCapital | 666.00K | -650.00K | 709.00K | 837.00K |
| ChangeInOtherCurrentLiabilities | -1.65M | -1.27M | -1.14M | 205.00K |
| ChangeInOtherCurrentAssets | 244.00K | 22.00K | 5.00K | -327.00K |
| ChangeInPayablesAndAccruedExpense | -445.00K | -2.33M | 2.02M | -1.43M |
| ChangeInAccruedExpense | 0.00 | |||
| ChangeInInterestPayable | 0.00 | |||
| ChangeInPayable | -1.43M | |||
| ChangeInAccountPayable | -1.43M | |||
| ChangeInPrepaidAssets | 694.00K | -99.00K | -582.00K | 828.00K |
| OtherNonCashItems | 1.55M | 1.36M | 1.19M | 57.00K |
| StockBasedCompensation | 3.13M | 4.45M | 5.81M | 5.66M |
| AssetImpairmentCharge | 951.00K | 0.00 | ||
| AmortizationOfSecurities | -986.00K | -1.06M | 231.00K | 615.00K |
| DepreciationAmortizationDepletion | 1.32M | 1.35M | 1.35M | 685.00K |
| DepreciationAndAmortization | 1.32M | 1.35M | 1.35M | 685.00K |
| Depreciation | 1.32M | 1.35M | 1.35M | 685.00K |
| OperatingGainsLosses | 302.00K | -30.00K | -596.00K | |
| GainLossOnInvestmentSecurities | -15.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 302.00K | -15.00K | -29.00K |
| NetIncomeFromContinuingOperations | -30.16M | -34.10M | -48.59M | -36.79M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SNSE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|